Study details
Enrolling now
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT IDNCT06903702ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 2.1 years
Ages
65+
Locations
7 sites in NJ, NY
About this study
This trial is testing whether allogeneic hematopoietic stem cell transplant, azacitidine and venetoclax, or maintenance therapy with azacitidine and venetoclax is more effective at preventing acute myeloid leukemia (AML) from returning.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Azacitidine (AZA)
- 2.Take Venetoclax
- 3.Undergo Allogeneic hematopoietic stem cell transplantation
PhasePhase 2
DrugAzacitidine (AZA)
Routeinjection
Primary goal1-year Relapse free survival (RFS)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
azacitidine, venetoclax
Drug routes
injection, subcutaneous, oral
Endpoints
Primary: 1-year Relapse free survival (RFS)
Secondary: Overall survival (OS)
Body systems
Oncology